Alzheimer's disease drug efficacy Aβ Bryostatin α-Secretase Biomarker PKC Skin fibroblasts Erk Synthetic analog of bryostatin PKC signaling is critical for the non-toxic degradation of amyloid precursor protein (APP) and inhibition of GSK3β, which controls phosphorylation of tau protein in Alzheimer's disease (AD). Thus the misregulation of PKC signaling could contribute to the origins of AD. Bryostatin, a potent PKC modulator, has the potential to ameliorate both the neurodegeneration and the recent memory loss associated with AD. As reported herein bryostatin and a potent synthetic analog (picolog) are found to cause stimulation of nonamyloidogenic pathways by increasing α-secretase activity and thus lowering the amount of toxic Aβ produced. Both bryostatin and picolog increased the secretion of the α-secretase product (s-APP-α) of APP at sub-nanomolar to nanomolar concentrations. A peripheral AD-Biomarker has previously been autopsyvalidated. This Biomarker, based on bradykinin-induced differential phosphorylation of Erk1 and Erk2, has been used here to test the therapeutic efficacy both for bryostatin and picolog. Both of these PKC activators are then shown to convert the AD Erk1/2 phenotype of fibroblasts into the phenotype of "normal" control skin fibroblasts. This conversion occurred for both the abnormal Erk1/2 phenotype induced by application of Aβ 1-42 to the fibroblasts or the phenotype observed for fibroblasts of AD patients. The Aβ 1-42 -induction, and PKC modulator reversal of the AD Erk1/2 biomarker phenotype demonstrate the AD-Biomarker's potential to monitor both disease progression and treatment response. Additionally, this first demonstration of the therapeutic potential in AD of a synthetically accessible bryostatin analog warrants further preclinical advancement.
Introduction
Accumulating evidence indicates a series of AD pathophysiological abnormalities in tissues other than in the brain, including blood, skin fibroblasts, and ocular tissues. In AD skin fibroblasts, several cellular and molecular abnormalities were observed, such as fibroblast K+ channels (Etcheberrigaray et al., 1993 (Etcheberrigaray et al., , 1994 , PKC isozymes (Govoni et al., 1993; Favit et al., 1998) , Ca 2+ signaling (Ito et al., 1994) , MAP kinase Erk1/2 phosphorylation (Zhao et al., 2002; Khan and Alkon, 2006) , and dysfunctional PP2A (Zhao et al., 2003) . Gene expression studies using familial AD (FAD) skin fibroblasts showed that the disease process may even start before the onset of cognitive decline (Nagasaka et al., 2005) . FAD fibroblasts were found to produce excess Aβ in culture fibroblasts (Citron et al., 1994; Johnston et al., 1994) . More recently, a new autopsy-confirmed, internally controlled, phosphorylated Erk1/2 peripheral biomarker in skin fibroblasts has been introduced ( Khan and Alkon, 2006; 2008) .
Controlled activation of α-secretase to reduce Aβ formation offers an alternative strategy to reduce Aβ and possibly treat AD. Furthermore, PKCɛ activation also activates endothelin converting enzyme activity, which reduces amyloid plaque pathology in transgenic mice (Choi et al., 2006) .
The macrocyclic lactone bryostatin, a natural product extracted from Bugula neritina, was found to activate PKC isozymes selectively (Etcheberrigaray et al., 2004) . These PKC isozymes then activate α-secretases directly or through MAP kinase (Alkon et al., 2007) . Due to the scarcity of bryostatin, its difficult isolation, and the complexity of the molecule, simplified and accessible synthetic analogs of bryostatin have been developed and have been found to be superior to bryostatin in some cases (Wender and Verma, 2008; Wender et al., 1998 Wender et al., , 2002 . In this study we showed that low concentrations (nM) of bryostatin and a synthetic analog termed, picolog, activated the non-amyloidogenic pathway by increasing the levels of α-secretase product(s). Both of these PKC activators were then shown to convert the AD Erk1/2 phenotype of fibroblasts into the phenotype of "normal" control skin fibroblasts. This conversion occurred for both the abnormal Erk1/2 phenotype induced by application of Aβ 1-42 to the fibroblasts or for the phenotype observed for fibroblasts of AD patients. These results
